The immunotherapy-based trial in UK healthcare has left plenty of hope upon treating glioblastoma through keeping a patient cancer-free.

With few cases of survival beyond one year in terminal glioblastoma, a 43-year-old is already nearing three years as there is no trace of the disease in him. Ben Trotman was diagnosed with the most stubborn form of cancer, in the brain, glioblastoma. His is an exceptional victory in the use of immunotherapy in the treatment of glioblastoma.

Ben was administered a single part of the immunotherapy treatment drug ipilimumab under the watch of a consultant oncologist referred to as Dr. Paul Mulholland at University College London Hospital (UCLH) and then started the normal care. Trotman has recovered unprecedentedly, which has led this NHS-funded healthcare trial,now known as Margaret's Trial, to seek more participants.

The trial involves administering immunotherapy prior to surgical operation, radiotherapy, or chemotherapy with the aim of ensuring that the immune system is boosted at a time when it is strongest. Healthcare professionals feel that this window-of-opportunity model has the potential to transform the clinical outcome of the patients with glioblastoma.

Funded through more than 1 million in a fundraising effort headed by an MP, Siobhain McDonagh, in her sister's memory, the late Baroness Margaret McDonagh, the trial has already received attention throughout the healthcare community. Trotman scans are clear, and this gives hope to patients and their families that battle the disease.